APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antibacterial (Drug) Resistance

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Antibacterial (Drug) Resistance Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025199 pages

Choose your research edition.

Industry ResearchAntibacterial (Drug) Resistance Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Antibacterial (Drug) Resistance Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Antibacterial (Drug) Resistance Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antibacterial (Drug) Resistance Market Outlook and Growth Opportunities 2026218 pages · $4,250 USDMarket Analysis & ForecastGlobal Antibacterial (Drug) Resistance Market Analysis and Forecast 2026-2032212 pages · $4,950 USD

Market perspective

The global Antibacterial (Drug) Resistance market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Antibacterial (Drug) Resistance is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Antibacterial (Drug) Resistance is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antibacterial (Drug) Resistance is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Antibacterial (Drug) Resistance is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Antibacterial (Drug) Resistance include Merck, Pfizer, GSK, VenatoRx Pharmaceuticals, PENDOPHARM, Osel, Novexel, NanoSafe Coatings and Nabriva Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Antibacterial (Drug) Resistance market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antibacterial (Drug) Resistance and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antibacterial (Drug) Resistance sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Antibacterial (Drug) Resistance market size, projected growth trends, production technologies, key applications, and end-use industries.

Antibacterial (Drug) Resistance Segment by Company

Merck

Pfizer

GSK

VenatoRx Pharmaceuticals

PENDOPHARM

Osel

Novexel

NanoSafe Coatings

Nabriva Therapeutics

Morphochem

Microbecide

Melinta Therapeutics

Lyndra

Isis Pharmaceuticals

InterMune

Evolva Holding

Demuris

ContraFect

Cerexa

Aventis Pharma

Austell Laboratories

Assembly Biosciences

Arpida

ANTABIO

Allergan

Acino Holdings

Achaogen

Absynth Biologics

Abbott Laboratories

AAIPharma Services

Antibacterial (Drug) Resistance Segment by Type

Ceftolozane-Tazobactam (Zerbaxa)

Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)

Ceftaroline Fosamil (Teflaro/ Zinforo)

Ceftazidime-Avibactam (Avycaz/ Zavicefta)

Telavancin (Vibativ)

Tedizolid Phosphate (Sivextro)

PHASE III DRUGS

Dalbavancin (Dalvance/ Xydalba)

Oritavancin (Orbactiv/ Nuvocid)

Fidaxomicin (Dificid / Dificlir)

Antibacterial (Drug) Resistance Segment by Application

Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)

Blood Stream Infections (BSI)

Community Acquired Bacterial Pneumonia (CABP)

Clostridium Difficile Infections (CDI)

Acute Bacterial Skin And Skin Structure Infections (ABSSSI)

Complicated Urinary Tract Infection (CUTI)

Complicated Intra-Abdominal Infections (CIAI)

Antibacterial (Drug) Resistance Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antibacterial (Drug) Resistance market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antibacterial (Drug) Resistance and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antibacterial (Drug) Resistance.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Antibacterial (Drug) Resistance market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Antibacterial (Drug) Resistance manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Antibacterial (Drug) Resistance in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Antibacterial (Drug) Resistance in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Antibacterial (Drug) Resistance Industry Trends Table 2. Antibacterial (Drug) Resistance Industry Drivers Table 3. Antibacterial (Drug) Resistance Industry Opportunities and Challenges Table 4. Antibacterial (Drug) Resistance Industry Restraints Table 5. Global Antibacterial (Drug) Resistance Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Antibacterial (Drug) Resistance Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Antibacterial (Drug) Resistance Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Antibacterial (Drug) Resistance Sales Market Share by Manufacturers Table 9. Global Antibacterial (Drug) Resistance Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Antibacterial (Drug) Resistance Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Antibacterial (Drug) Resistance Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Antibacterial (Drug) Resistance Manufacturers, Product Type & Application Table 13. Global Antibacterial (Drug) Resistance Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Antibacterial (Drug) Resistance by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Ceftolozane-Tazobactam (Zerbaxa) Table 17. Major Manufacturers of Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio) Table 18. Major Manufacturers of Ceftaroline Fosamil (Teflaro/ Zinforo) Table 19. Major Manufacturers of Ceftazidime-Avibactam (Avycaz/ Zavicefta) Table 20. Major Manufacturers of Telavancin (Vibativ) Table 21. Major Manufacturers of Tedizolid Phosphate (Sivextro) Table 22. Major Manufacturers of PHASE III DRUGS Table 23. Major Manufacturers of Dalbavancin (Dalvance/ Xydalba) Table 24. Major Manufacturers of Oritavancin (Orbactiv/ Nuvocid) Table 25. Major Manufacturers of Fidaxomicin (Dificid / Dificlir) Table 26. Global Antibacterial (Drug) Resistance Sales by Type 2021 VS 2025 VS 2032 (k units) Table 27. Global Antibacterial (Drug) Resistance Sales by Type (2021-2026) & (k units) Table 28. Global Antibacterial (Drug) Resistance Sales by Type (2027-2032) & (k units) Table 29. Global Antibacterial (Drug) Resistance Sales Market Share by Type (2021-2026) Table 30. Global Antibacterial (Drug) Resistance Sales Market Share by Type (2027-2032) Table 31. Global Antibacterial (Drug) Resistance Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 32. Global Antibacterial (Drug) Resistance Revenue by Type (2021-2026) & (k units) Table 33. Global Antibacterial (Drug) Resistance Revenue by Type (2027-2032) & (k units) Table 34. Global Antibacterial (Drug) Resistance Revenue Market Share by Type (2021-2026) Table 35. Global Antibacterial (Drug) Resistance Revenue Market Share by Type (2027-2032) Table 36. Major Manufacturers of Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP) Table 37. Major Manufacturers of Blood Stream Infections (BSI) Table 38. Major Manufacturers of Community Acquired Bacterial Pneumonia (CABP) Table 39. Major Manufacturers of Clostridium Difficile Infections (CDI) Table 40. Major Manufacturers of Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Table 41. Major Manufacturers of Complicated Urinary Tract Infection (CUTI) Table 42. Major Manufacturers of Complicated Intra-Abdominal Infections (CIAI) Table 43. Global Antibacterial (Drug) Resistance Sales by Application 2021 VS 2025 VS 2032 (k units) Table 44. Global Antibacterial (Drug) Resistance Sales by Application (2021-2026) & (k units) Table 45. Global Antibacterial (Drug) Resistance Sales by Application (2027-2032) & (k units) Table 46. Global Antibacterial (Drug) Resistance Sales Market Share by Application (2021-2026) Table 47. Global Antibacterial (Drug) Resistance Sales Market Share by Application (2027-2032) Table 48. Global Antibacterial (Drug) Resistance Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 49. Global Antibacterial (Drug) Resistance Revenue by Application (2021-2026) & (k units) Table 50. Global Antibacterial (Drug) Resistance Revenue by Application (2027-2032) & (k units) Table 51. Global Antibacterial (Drug) Resistance Revenue Market Share by Application (2021-2026) Table 52. Global Antibacterial (Drug) Resistance Revenue Market Share by Application (2027-2032) Table 53. Global Antibacterial (Drug) Resistance Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 54. Global Antibacterial (Drug) Resistance Sales by Region (2021-2026) & (k units) Table 55. Global Antibacterial (Drug) Resistance Sales Market Share by Region (2021-2026) Table 56. Global Antibacterial (Drug) Resistance Sales Forecasted by Region (2027-2032) & (k units) Table 57. Global Antibacterial (Drug) Resistance Sales Forecasted Market Share by Region (2027-2032) Table 58. North America Antibacterial (Drug) Resistance Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 59. North America Antibacterial (Drug) Resistance Sales by Country (2021-2026) & (k units) Table 60. North America Antibacterial (Drug) Resistance Sales by Country (2027-2032) & (k units) Table 61. Europe Antibacterial (Drug) Resistance Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 62. Europe Antibacterial (Drug) Resistance Sales by Country (2021-2026) & (k units) Table 63. Europe Antibacterial (Drug) Resistance Sales by Country (2027-2032) & (k units) Table 64. Asia Pacific Antibacterial (Drug) Resistance Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 65. Asia Pacific Antibacterial (Drug) Resistance Sales by Country (2021-2026) & (k units) Table 66. Asia Pacific Antibacterial (Drug) Resistance Sales by Country (2027-2032) & (k units) Table 67. South America, Middle East and Africa Antibacterial (Drug) Resistance Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 68. South America, Middle East and Africa Antibacterial (Drug) Resistance Sales by Country (2021-2026) & (k units) Table 69. South America, Middle East and Africa Antibacterial (Drug) Resistance Sales by Country (2027-2032) & (k units) Table 70. Global Antibacterial (Drug) Resistance Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 71. Global Antibacterial (Drug) Resistance Revenue by Region (2021-2026) & (US$ Million) Table 72. Global Antibacterial (Drug) Resistance Revenue by Region (2027-2032) & (US$ Million) Table 73. Global Antibacterial (Drug) Resistance Revenue Market Share by Region (2021-2026) Table 74. Global Antibacterial (Drug) Resistance Revenue Market Share by Region (2027-2032) Table 75. Merck Company Information Table 76. Merck Business Overview Table 77. Merck Antibacterial (Drug) Resistance Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Merck Antibacterial (Drug) Resistance Product Portfolio Table 79. Merck Recent Development Table 80. Pfizer Company Information Table 81. Pfizer Business Overview Table 82. Pfizer Antibacterial (Drug) Resistance Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Pfizer Antibacterial (Drug) Resistance Product Portfolio Table 84. Pfizer Recent Development Table 85. GSK Company Information Table 86. GSK Business Overview Table 87. GSK Antibacterial (Drug) Resistance Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. GSK Antibacterial (Drug) Resistance Product Portfolio Table 89. GSK Recent Development Table 90. VenatoRx Pharmaceuticals Company Information Table 91. VenatoRx Pharmaceuticals Business Overview Table 92. VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Product Portfolio Table 94. VenatoRx Pharmaceuticals Recent Development Table 95. PENDOPHARM Company Information Table 96. PENDOPHARM Business Overview Table 97. PENDOPHARM Antibacterial (Drug) Resistance Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. PENDOPHARM Antibacterial (Drug) Resistance Product Portfolio Table 99. PENDOPHARM Recent Development Table 100. Osel Company Information Table 101. Osel Business Overview Table 102. Osel Antibacterial (Drug) Resistance Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Osel Antibacterial (Drug) Resistance Product Portfolio Table 104. Osel Recent Development Table 105. Novexel Company Information Table 106. Novexel Business Overview Table 107. Novexel Antibacterial (Drug) Resistance Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Novexel Antibacterial (Drug) Resistance Product Portfolio Table 109. Novexel Recent Development Table 110. NanoSafe Coatings Company Information Table 111. NanoSafe Coatings Business Overview Table 112. NanoSafe Coatings Antibacterial (Drug) Resistance Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. NanoSafe Coatings Antibacterial (Drug) Resistance Product Portfolio Table 114. NanoSafe Coatings Recent Development Table 115. Nabriva Therapeutics Company Information Table 116. Nabriva Therapeutics Business Overview Table 117. Nabriva Therapeutics Antibacterial (Drug) Resistance Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Nabriva Therapeutics Antibacterial (Drug) Resistance Product Portfolio Table 119. Nabriva Therapeutics Recent Development Table 120. Morphochem Company Information Table 121. Morphochem Business Overview Table 122. Morphochem Antibacterial (Drug) Resistance Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. Morphochem Antibacterial (Drug) Resistance Product Portfolio Table 124. Morphochem Recent Development Table 125. Microbecide Company Information Table 126. Microbecide Business Overview Table 127. Microbecide Antibacterial (Drug) Resistance Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. Microbecide Antibacterial (Drug) Resistance Product Portfolio Table 129. Microbecide Recent Development Table 130. Melinta Therapeutics Company Information Table 131. Melinta Therapeutics Business Overview Table 132. Melinta Therapeutics Antibacterial (Drug) Resistance Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 133. Melinta Therapeutics Antibacterial (Drug) Resistance Product Portfolio Table 134. Melinta Therapeutics Recent Development Table 135. Lyndra Company Information Table 136. Lyndra Business Overview Table 137. Lyndra Antibacterial (Drug) Resistance Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 138. Lyndra Antibacterial (Drug) Resistance Product Portfolio Table 139. Lyndra Recent Development Table 140. Isis Pharmaceuticals Company Information Table 141. Isis Pharmaceuticals Business Overview Table 142. Isis Pharmaceuticals Antibacterial (Drug) Resistance Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 143. Isis Pharmaceuticals Antibacterial (Drug) Resistance Product Portfolio Table 144. Isis Pharmaceuticals Recent Development Table 145. InterMune Company Information Table 146. InterMune Business Overview Table 147. InterMune Antibacterial (Drug) Resistance Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 148. InterMune Antibacterial (Drug) Resistance Product Portfolio Table 149. InterMune Recent Development Table 150. Evolva Holding Company Information Table 151. Evolva Holding Business Overview Table 152. Evolva Holding Antibacterial (Drug) Resistance Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 153. Evolva Holding Antibacterial (Drug) Resistance Product Portfolio Table 154. Evolva Holding Recent Development Table 155. Demuris Company Information Table 156. Demuris Business Overview Table 157. Demuris Antibacterial (Drug) Resistance Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 158. Demuris Antibacterial (Drug) Resistance Product Portfolio Table 159. Demuris Recent Development Table 160. ContraFect Company Information Table 161. ContraFect Business Overview Table 162. ContraFect Antibacterial (Drug) Resistance Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 163. ContraFect Antibacterial (Drug) Resistance Product Portfolio Table 164. ContraFect Recent Development Table 165. Cerexa Company Information Table 166. Cerexa Business Overview Table 167. Cerexa Antibacterial (Drug) Resistance Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 168. Cerexa Antibacterial (Drug) Resistance Product Portfolio Table 169. Cerexa Recent Development Table 170. Aventis Pharma Company Information Table 171. Aventis Pharma Business Overview Table 172. Aventis Pharma Antibacterial (Drug) Resistance Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 173. Aventis Pharma Antibacterial (Drug) Resistance Product Portfolio Table 174. Aventis Pharma Recent Development Table 175. Austell Laboratories Company Information Table 176. Austell Laboratories Business Overview Table 177. Austell Laboratories Antibacterial (Drug) Resistance Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 178. Austell Laboratories Antibacterial (Drug) Resistance Product Portfolio Table 179. Austell Laboratories Recent Development Table 180. Assembly Biosciences Company Information Table 181. Assembly Biosciences Business Overview Table 182. Assembly Biosciences Antibacterial (Drug) Resistance Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 183. Assembly Biosciences Antibacterial (Drug) Resistance Product Portfolio Table 184. Assembly Biosciences Recent Development Table 185. Arpida Company Information Table 186. Arpida Business Overview Table 187. Arpida Antibacterial (Drug) Resistance Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 188. Arpida Antibacterial (Drug) Resistance Product Portfolio Table 189. Arpida Recent Development Table 190. ANTABIO Company Information Table 191. ANTABIO Business Overview Table 192. ANTABIO Antibacterial (Drug) Resistance Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 193. ANTABIO Antibacterial (Drug) Resistance Product Portfolio Table 194. ANTABIO Recent Development Table 195. Allergan Company Information Table 196. Allergan Business Overview Table 197. Allergan Antibacterial (Drug) Resistance Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 198. Allergan Antibacterial (Drug) Resistance Product Portfolio Table 199. Allergan Recent Development Table 200. Acino Holdings Company Information Table 201. Acino Holdings Business Overview Table 202. Acino Holdings Antibacterial (Drug) Resistance Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 203. Acino Holdings Antibacterial (Drug) Resistance Product Portfolio Table 204. Acino Holdings Recent Development Table 205. Achaogen Company Information Table 206. Achaogen Business Overview Table 207. Achaogen Antibacterial (Drug) Resistance Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 208. Achaogen Antibacterial (Drug) Resistance Product Portfolio Table 209. Achaogen Recent Development Table 210. Absynth Biologics Company Information Table 211. Absynth Biologics Business Overview Table 212. Absynth Biologics Antibacterial (Drug) Resistance Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 213. Absynth Biologics Antibacterial (Drug) Resistance Product Portfolio Table 214. Absynth Biologics Recent Development Table 215. Abbott Laboratories Company Information Table 216. Abbott Laboratories Business Overview Table 217. Abbott Laboratories Antibacterial (Drug) Resistance Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 218. Abbott Laboratories Antibacterial (Drug) Resistance Product Portfolio Table 219. Abbott Laboratories Recent Development Table 220. AAIPharma Services Company Information Table 221. AAIPharma Services Business Overview Table 222. AAIPharma Services Antibacterial (Drug) Resistance Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 223. AAIPharma Services Antibacterial (Drug) Resistance Product Portfolio Table 224. AAIPharma Services Recent Development Table 225. Key Raw Materials Table 226. Raw Materials Key Suppliers Table 227. Antibacterial (Drug) Resistance Distributors List Table 228. Antibacterial (Drug) Resistance Customers List Table 229. Research Programs/Design for This Report Table 230. Authors List of This Report Table 231. Secondary Sources Table 232. Primary Sources List of Figures Figure 1. Antibacterial (Drug) Resistance Product Image Figure 2. Global Antibacterial (Drug) Resistance Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antibacterial (Drug) Resistance Market Size (2021-2032) & (US$ Million) Figure 4. Global Antibacterial (Drug) Resistance Sales (2021-2032) & (k units) Figure 5. Global Antibacterial (Drug) Resistance Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Antibacterial (Drug) Resistance Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Ceftolozane-Tazobactam (Zerbaxa) Image Figure 9. Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio) Image Figure 10. Ceftaroline Fosamil (Teflaro/ Zinforo) Image Figure 11. Ceftazidime-Avibactam (Avycaz/ Zavicefta) Image Figure 12. Telavancin (Vibativ) Image Figure 13. Tedizolid Phosphate (Sivextro) Image Figure 14. PHASE III DRUGS Image Figure 15. Dalbavancin (Dalvance/ Xydalba) Image Figure 16. Oritavancin (Orbactiv/ Nuvocid) Image Figure 17. Fidaxomicin (Dificid / Dificlir) Image Figure 18. Global Antibacterial (Drug) Resistance Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 19. Global Antibacterial (Drug) Resistance Sales Market Share 2021 VS 2025 VS 2032 Figure 20. Global Antibacterial (Drug) Resistance Sales Market Share by Type (2021-2032) Figure 21. Global Antibacterial (Drug) Resistance Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Antibacterial (Drug) Resistance Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Antibacterial (Drug) Resistance Revenue Market Share by Type (2021-2032) Figure 24. Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP) Image Figure 25. Blood Stream Infections (BSI) Image Figure 26. Community Acquired Bacterial Pneumonia (CABP) Image Figure 27. Clostridium Difficile Infections (CDI) Image Figure 28. Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Image Figure 29. Complicated Urinary Tract Infection (CUTI) Image Figure 30. Complicated Intra-Abdominal Infections (CIAI) Image Figure 31. Global Antibacterial (Drug) Resistance Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 32. Global Antibacterial (Drug) Resistance Sales Market Share 2021 VS 2025 VS 2032 Figure 33. Global Antibacterial (Drug) Resistance Sales Market Share by Application (2021-2032) Figure 34. Global Antibacterial (Drug) Resistance Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 35. Global Antibacterial (Drug) Resistance Revenue Market Share 2021 VS 2025 VS 2032 Figure 36. Global Antibacterial (Drug) Resistance Revenue Market Share by Application (2021-2032) Figure 37. North America Antibacterial (Drug) Resistance Sales and Growth Rate (2021-2032) & (k units) Figure 38. North America Antibacterial (Drug) Resistance Sales Market Share by Country (2021-2032) Figure 39. U.S. Antibacterial (Drug) Resistance Sales and Growth Rate (2021-2032) & (k units) Figure 40. Canada Antibacterial (Drug) Resistance Sales and Growth Rate (2021-2032) & (k units) Figure 41. Mexico Antibacterial (Drug) Resistance Sales and Growth Rate (2021-2032) & (k units) Figure 42. Europe Antibacterial (Drug) Resistance Sales and Growth Rate (2021-2032) & (k units) Figure 43. Europe Antibacterial (Drug) Resistance Sales Market Share by Country (2021-2032) Figure 44. Germany Antibacterial (Drug) Resistance Sales and Growth Rate (2021-2032) & (k units) Figure 45. France Antibacterial (Drug) Resistance Sales and Growth Rate (2021-2032) & (k units) Figure 46. U.K. Antibacterial (Drug) Resistance Sales and Growth Rate (2021-2032) & (k units) Figure 47. Italy Antibacterial (Drug) Resistance Sales and Growth Rate (2021-2032) & (k units) Figure 48. Netherlands Antibacterial (Drug) Resistance Sales and Growth Rate (2021-2032) & (k units) Figure 49. Asia Pacific Antibacterial (Drug) Resistance Sales and Growth Rate (2021-2032) & (k units) Figure 50. Asia Pacific Antibacterial (Drug) Resistance Sales Market Share by Country (2021-2032) Figure 51. China Antibacterial (Drug) Resistance Sales and Growth Rate (2021-2032) & (k units) Figure 52. Japan Antibacterial (Drug) Resistance Sales and Growth Rate (2021-2032) & (k units) Figure 53. South Korea Antibacterial (Drug) Resistance Sales and Growth Rate (2021-2032) & (k units) Figure 54. Southeast Asia Antibacterial (Drug) Resistance Sales and Growth Rate (2021-2032) & (k units) Figure 55. India Antibacterial (Drug) Resistance Sales and Growth Rate (2021-2032) & (k units) Figure 56. Australia Antibacterial (Drug) Resistance Sales and Growth Rate (2021-2032) & (k units) Figure 57. South America, Middle East and Africa Antibacterial (Drug) Resistance Sales and Growth Rate (2021-2032) & (k units) Figure 58. South America, Middle East and Africa Antibacterial (Drug) Resistance Sales Market Share by Country (2021-2032) Figure 59. Brazil Antibacterial (Drug) Resistance Sales and Growth Rate (2021-2032) & (k units) Figure 60. South Africa Antibacterial (Drug) Resistance Sales and Growth Rate (2021-2032) & (k units) Figure 61. Saudi Arabia Antibacterial (Drug) Resistance Sales and Growth Rate (2021-2032) & (k units) Figure 62. Turkey Antibacterial (Drug) Resistance Sales and Growth Rate (2021-2032) & (k units) Figure 63. Argentina Antibacterial (Drug) Resistance Sales and Growth Rate (2021-2032) & (k units) Figure 64. UAE Antibacterial (Drug) Resistance Sales and Growth Rate (2021-2032) & (k units) Figure 65. Egypt Antibacterial (Drug) Resistance Sales and Growth Rate (2021-2032) & (k units) Figure 66. Chile Antibacterial (Drug) Resistance Sales and Growth Rate (2021-2032) & (k units) Figure 67. Global Antibacterial (Drug) Resistance Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 68. Global Antibacterial (Drug) Resistance Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 69. North America Antibacterial (Drug) Resistance Revenue (2021-2032) & (US$ Million) Figure 70. North America Antibacterial (Drug) Resistance Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 71. Europe Antibacterial (Drug) Resistance Revenue (2021-2032) & (US$ Million) Figure 72. Europe Antibacterial (Drug) Resistance Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 73. Asia-Pacific Antibacterial (Drug) Resistance Revenue (2021-2032) & (US$ Million) Figure 74. Asia-Pacific Antibacterial (Drug) Resistance Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 75. South America, Middle East and Africa Antibacterial (Drug) Resistance Revenue (2021-2032) & (US$ Million) Figure 76. South America, Middle East and Africa Antibacterial (Drug) Resistance Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 77. Antibacterial (Drug) Resistance Value Chain Figure 78. Manufacturing Cost Structure Figure 79. Antibacterial (Drug) Resistance Production Mode & Process Figure 80. Direct Comparison with Distribution Share Figure 81. Distributors Profiles Figure 82. Years Considered Figure 83. Research Process Figure 84. Key Executives Interviewed

Scope & coverage.

Types
  • Ceftolozane-Tazobactam (Zerbaxa)
  • Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)
  • Ceftaroline Fosamil (Teflaro/ Zinforo)
  • Ceftazidime-Avibactam (Avycaz/ Zavicefta)
  • Telavancin (Vibativ)
  • Tedizolid Phosphate (Sivextro)
  • PHASE III DRUGS
  • Dalbavancin (Dalvance/ Xydalba)
  • Oritavancin (Orbactiv/ Nuvocid)
  • Fidaxomicin (Dificid / Dificlir)
Applications
  • Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
  • Blood Stream Infections (BSI)
  • Community Acquired Bacterial Pneumonia (CABP)
  • Clostridium Difficile Infections (CDI)
  • Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
  • Complicated Urinary Tract Infection (CUTI)
  • Complicated Intra-Abdominal Infections (CIAI)
Companies covered
  • Merck
  • Pfizer
  • GSK
  • VenatoRx Pharmaceuticals
  • PENDOPHARM
  • Osel
  • Novexel
  • NanoSafe Coatings
  • Nabriva Therapeutics
  • Morphochem
  • Microbecide
  • Melinta Therapeutics
  • Lyndra
  • Isis Pharmaceuticals
  • InterMune
  • Evolva Holding
  • Demuris
  • ContraFect
  • Cerexa
  • Aventis Pharma
  • Austell Laboratories
  • Assembly Biosciences
  • Arpida
  • ANTABIO
  • Allergan
  • Acino Holdings
  • Achaogen
  • Absynth Biologics
  • Abbott Laboratories
  • AAIPharma Services

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Antibacterial (Drug) Resistance Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Antibacterial (Drug) Resistance Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Antibacterial (Drug) Resistance Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Antibacterial (Drug) Resistance Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Antibacterial (Drug) Resistance Market Dynamics
  1. 2.1 Antibacterial (Drug) Resistance Industry Trends
  2. 2.2 Antibacterial (Drug) Resistance Industry Drivers
  3. 2.3 Antibacterial (Drug) Resistance Industry Opportunities and Challenges
  4. 2.4 Antibacterial (Drug) Resistance Industry Restraints
3 Antibacterial (Drug) Resistance Market by Manufacturers
  1. 3.1 Global Antibacterial (Drug) Resistance Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Antibacterial (Drug) Resistance Sales by Manufacturers (2021-2026)
  3. 3.3 Global Antibacterial (Drug) Resistance Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Antibacterial (Drug) Resistance Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Antibacterial (Drug) Resistance Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Antibacterial (Drug) Resistance Manufacturers, Product Type & Application
  7. 3.7 Global Antibacterial (Drug) Resistance Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Antibacterial (Drug) Resistance Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Antibacterial (Drug) Resistance Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Antibacterial (Drug) Resistance Tier 1, Tier 2, and Tier 3
4 Antibacterial (Drug) Resistance Market by Type
  1. 4.1 Antibacterial (Drug) Resistance Type Introduction
  2. 4.1.1 Ceftolozane-Tazobactam (Zerbaxa)
  3. 4.1.2 Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)
  4. 4.1.3 Ceftaroline Fosamil (Teflaro/ Zinforo)
  5. 4.1.4 Ceftazidime-Avibactam (Avycaz/ Zavicefta)
  6. 4.1.5 Telavancin (Vibativ)
  7. 4.1.6 Tedizolid Phosphate (Sivextro)
  8. 4.1.7 PHASE III DRUGS
  9. 4.1.8 Dalbavancin (Dalvance/ Xydalba)
  10. 4.1.9 Oritavancin (Orbactiv/ Nuvocid)
  11. 4.1.10 Fidaxomicin (Dificid / Dificlir)
  12. 4.2 Global Antibacterial (Drug) Resistance Sales by Type
  13. 4.2.1 Global Antibacterial (Drug) Resistance Sales by Type (2021 VS 2025 VS 2032)
  14. 4.2.2 Global Antibacterial (Drug) Resistance Sales by Type (2021-2032)
  15. 4.2.3 Global Antibacterial (Drug) Resistance Sales Market Share by Type (2021-2032)
  16. 4.3 Global Antibacterial (Drug) Resistance Revenue by Type
  17. 4.3.1 Global Antibacterial (Drug) Resistance Revenue by Type (2021 VS 2025 VS 2032)
  18. 4.3.2 Global Antibacterial (Drug) Resistance Revenue by Type (2021-2032)
  19. 4.3.3 Global Antibacterial (Drug) Resistance Revenue Market Share by Type (2021-2032)
5 Antibacterial (Drug) Resistance Market by Application
  1. 5.1 Antibacterial (Drug) Resistance Application Introduction
  2. 5.1.1 Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
  3. 5.1.2 Blood Stream Infections (BSI)
  4. 5.1.3 Community Acquired Bacterial Pneumonia (CABP)
  5. 5.1.4 Clostridium Difficile Infections (CDI)
  6. 5.1.5 Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
  7. 5.1.6 Complicated Urinary Tract Infection (CUTI)
  8. 5.1.7 Complicated Intra-Abdominal Infections (CIAI)
  9. 5.2 Global Antibacterial (Drug) Resistance Sales by Application
  10. 5.2.1 Global Antibacterial (Drug) Resistance Sales by Application (2021 VS 2025 VS 2032)
  11. 5.2.2 Global Antibacterial (Drug) Resistance Sales by Application (2021-2032)
  12. 5.2.3 Global Antibacterial (Drug) Resistance Sales Market Share by Application (2021-2032)
  13. 5.3 Global Antibacterial (Drug) Resistance Revenue by Application
  14. 5.3.1 Global Antibacterial (Drug) Resistance Revenue by Application (2021 VS 2025 VS 2032)
  15. 5.3.2 Global Antibacterial (Drug) Resistance Revenue by Application (2021-2032)
  16. 5.3.3 Global Antibacterial (Drug) Resistance Revenue Market Share by Application (2021-2032)
6 Global Antibacterial (Drug) Resistance Sales by Region
  1. 6.1 Global Antibacterial (Drug) Resistance Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Antibacterial (Drug) Resistance Sales by Region (2021-2032)
  3. 6.2.1 Global Antibacterial (Drug) Resistance Sales by Region (2021-2026)
  4. 6.2.2 Global Antibacterial (Drug) Resistance Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Antibacterial (Drug) Resistance Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Antibacterial (Drug) Resistance Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Antibacterial (Drug) Resistance Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Antibacterial (Drug) Resistance Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Antibacterial (Drug) Resistance Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Antibacterial (Drug) Resistance Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Antibacterial (Drug) Resistance Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Antibacterial (Drug) Resistance Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Antibacterial (Drug) Resistance Revenue by Region
  1. 7.1 Global Antibacterial (Drug) Resistance Revenue by Region
  2. 7.1.1 Global Antibacterial (Drug) Resistance Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Antibacterial (Drug) Resistance Revenue by Region (2021-2026)
  4. 7.1.3 Global Antibacterial (Drug) Resistance Revenue by Region (2027-2032)
  5. 7.1.4 Global Antibacterial (Drug) Resistance Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Antibacterial (Drug) Resistance Revenue (2021-2032)
  8. 7.2.2 North America Antibacterial (Drug) Resistance Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Antibacterial (Drug) Resistance Revenue (2021-2032)
  11. 7.3.2 Europe Antibacterial (Drug) Resistance Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Antibacterial (Drug) Resistance Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Antibacterial (Drug) Resistance Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Antibacterial (Drug) Resistance Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Antibacterial (Drug) Resistance Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck
  2. 8.1.1 Merck Company Information
  3. 8.1.2 Merck Business Overview
  4. 8.1.3 Merck Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Merck Antibacterial (Drug) Resistance Product Portfolio
  6. 8.1.5 Merck Recent Developments
  7. 8.2 Pfizer
  8. 8.2.1 Pfizer Company Information
  9. 8.2.2 Pfizer Business Overview
  10. 8.2.3 Pfizer Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer Antibacterial (Drug) Resistance Product Portfolio
  12. 8.2.5 Pfizer Recent Developments
  13. 8.3 GSK
  14. 8.3.1 GSK Company Information
  15. 8.3.2 GSK Business Overview
  16. 8.3.3 GSK Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 GSK Antibacterial (Drug) Resistance Product Portfolio
  18. 8.3.5 GSK Recent Developments
  19. 8.4 VenatoRx Pharmaceuticals
  20. 8.4.1 VenatoRx Pharmaceuticals Company Information
  21. 8.4.2 VenatoRx Pharmaceuticals Business Overview
  22. 8.4.3 VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Product Portfolio
  24. 8.4.5 VenatoRx Pharmaceuticals Recent Developments
  25. 8.5 PENDOPHARM
  26. 8.5.1 PENDOPHARM Company Information
  27. 8.5.2 PENDOPHARM Business Overview
  28. 8.5.3 PENDOPHARM Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 PENDOPHARM Antibacterial (Drug) Resistance Product Portfolio
  30. 8.5.5 PENDOPHARM Recent Developments
  31. 8.6 Osel
  32. 8.6.1 Osel Company Information
  33. 8.6.2 Osel Business Overview
  34. 8.6.3 Osel Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Osel Antibacterial (Drug) Resistance Product Portfolio
  36. 8.6.5 Osel Recent Developments
  37. 8.7 Novexel
  38. 8.7.1 Novexel Company Information
  39. 8.7.2 Novexel Business Overview
  40. 8.7.3 Novexel Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Novexel Antibacterial (Drug) Resistance Product Portfolio
  42. 8.7.5 Novexel Recent Developments
  43. 8.8 NanoSafe Coatings
  44. 8.8.1 NanoSafe Coatings Company Information
  45. 8.8.2 NanoSafe Coatings Business Overview
  46. 8.8.3 NanoSafe Coatings Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 NanoSafe Coatings Antibacterial (Drug) Resistance Product Portfolio
  48. 8.8.5 NanoSafe Coatings Recent Developments
  49. 8.9 Nabriva Therapeutics
  50. 8.9.1 Nabriva Therapeutics Company Information
  51. 8.9.2 Nabriva Therapeutics Business Overview
  52. 8.9.3 Nabriva Therapeutics Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Nabriva Therapeutics Antibacterial (Drug) Resistance Product Portfolio
  54. 8.9.5 Nabriva Therapeutics Recent Developments
  55. 8.10 Morphochem
  56. 8.10.1 Morphochem Company Information
  57. 8.10.2 Morphochem Business Overview
  58. 8.10.3 Morphochem Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Morphochem Antibacterial (Drug) Resistance Product Portfolio
  60. 8.10.5 Morphochem Recent Developments
  61. 8.11 Microbecide
  62. 8.11.1 Microbecide Company Information
  63. 8.11.2 Microbecide Business Overview
  64. 8.11.3 Microbecide Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Microbecide Antibacterial (Drug) Resistance Product Portfolio
  66. 8.11.5 Microbecide Recent Developments
  67. 8.12 Melinta Therapeutics
  68. 8.12.1 Melinta Therapeutics Company Information
  69. 8.12.2 Melinta Therapeutics Business Overview
  70. 8.12.3 Melinta Therapeutics Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Melinta Therapeutics Antibacterial (Drug) Resistance Product Portfolio
  72. 8.12.5 Melinta Therapeutics Recent Developments
  73. 8.13 Lyndra
  74. 8.13.1 Lyndra Company Information
  75. 8.13.2 Lyndra Business Overview
  76. 8.13.3 Lyndra Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Lyndra Antibacterial (Drug) Resistance Product Portfolio
  78. 8.13.5 Lyndra Recent Developments
  79. 8.14 Isis Pharmaceuticals
  80. 8.14.1 Isis Pharmaceuticals Company Information
  81. 8.14.2 Isis Pharmaceuticals Business Overview
  82. 8.14.3 Isis Pharmaceuticals Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Isis Pharmaceuticals Antibacterial (Drug) Resistance Product Portfolio
  84. 8.14.5 Isis Pharmaceuticals Recent Developments
  85. 8.15 InterMune
  86. 8.15.1 InterMune Company Information
  87. 8.15.2 InterMune Business Overview
  88. 8.15.3 InterMune Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 InterMune Antibacterial (Drug) Resistance Product Portfolio
  90. 8.15.5 InterMune Recent Developments
  91. 8.16 Evolva Holding
  92. 8.16.1 Evolva Holding Company Information
  93. 8.16.2 Evolva Holding Business Overview
  94. 8.16.3 Evolva Holding Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Evolva Holding Antibacterial (Drug) Resistance Product Portfolio
  96. 8.16.5 Evolva Holding Recent Developments
  97. 8.17 Demuris
  98. 8.17.1 Demuris Company Information
  99. 8.17.2 Demuris Business Overview
  100. 8.17.3 Demuris Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Demuris Antibacterial (Drug) Resistance Product Portfolio
  102. 8.17.5 Demuris Recent Developments
  103. 8.18 ContraFect
  104. 8.18.1 ContraFect Company Information
  105. 8.18.2 ContraFect Business Overview
  106. 8.18.3 ContraFect Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 ContraFect Antibacterial (Drug) Resistance Product Portfolio
  108. 8.18.5 ContraFect Recent Developments
  109. 8.19 Cerexa
  110. 8.19.1 Cerexa Company Information
  111. 8.19.2 Cerexa Business Overview
  112. 8.19.3 Cerexa Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Cerexa Antibacterial (Drug) Resistance Product Portfolio
  114. 8.19.5 Cerexa Recent Developments
  115. 8.20 Aventis Pharma
  116. 8.20.1 Aventis Pharma Company Information
  117. 8.20.2 Aventis Pharma Business Overview
  118. 8.20.3 Aventis Pharma Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Aventis Pharma Antibacterial (Drug) Resistance Product Portfolio
  120. 8.20.5 Aventis Pharma Recent Developments
  121. 8.21 Austell Laboratories
  122. 8.21.1 Austell Laboratories Company Information
  123. 8.21.2 Austell Laboratories Business Overview
  124. 8.21.3 Austell Laboratories Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Austell Laboratories Antibacterial (Drug) Resistance Product Portfolio
  126. 8.21.5 Austell Laboratories Recent Developments
  127. 8.22 Assembly Biosciences
  128. 8.22.1 Assembly Biosciences Company Information
  129. 8.22.2 Assembly Biosciences Business Overview
  130. 8.22.3 Assembly Biosciences Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Assembly Biosciences Antibacterial (Drug) Resistance Product Portfolio
  132. 8.22.5 Assembly Biosciences Recent Developments
  133. 8.23 Arpida
  134. 8.23.1 Arpida Company Information
  135. 8.23.2 Arpida Business Overview
  136. 8.23.3 Arpida Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2021-2026)
  137. 8.23.4 Arpida Antibacterial (Drug) Resistance Product Portfolio
  138. 8.23.5 Arpida Recent Developments
  139. 8.24 ANTABIO
  140. 8.24.1 ANTABIO Company Information
  141. 8.24.2 ANTABIO Business Overview
  142. 8.24.3 ANTABIO Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2021-2026)
  143. 8.24.4 ANTABIO Antibacterial (Drug) Resistance Product Portfolio
  144. 8.24.5 ANTABIO Recent Developments
  145. 8.25 Allergan
  146. 8.25.1 Allergan Company Information
  147. 8.25.2 Allergan Business Overview
  148. 8.25.3 Allergan Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2021-2026)
  149. 8.25.4 Allergan Antibacterial (Drug) Resistance Product Portfolio
  150. 8.25.5 Allergan Recent Developments
  151. 8.26 Acino Holdings
  152. 8.26.1 Acino Holdings Company Information
  153. 8.26.2 Acino Holdings Business Overview
  154. 8.26.3 Acino Holdings Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2021-2026)
  155. 8.26.4 Acino Holdings Antibacterial (Drug) Resistance Product Portfolio
  156. 8.26.5 Acino Holdings Recent Developments
  157. 8.27 Achaogen
  158. 8.27.1 Achaogen Company Information
  159. 8.27.2 Achaogen Business Overview
  160. 8.27.3 Achaogen Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2021-2026)
  161. 8.27.4 Achaogen Antibacterial (Drug) Resistance Product Portfolio
  162. 8.27.5 Achaogen Recent Developments
  163. 8.28 Absynth Biologics
  164. 8.28.1 Absynth Biologics Company Information
  165. 8.28.2 Absynth Biologics Business Overview
  166. 8.28.3 Absynth Biologics Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2021-2026)
  167. 8.28.4 Absynth Biologics Antibacterial (Drug) Resistance Product Portfolio
  168. 8.28.5 Absynth Biologics Recent Developments
  169. 8.29 Abbott Laboratories
  170. 8.29.1 Abbott Laboratories Company Information
  171. 8.29.2 Abbott Laboratories Business Overview
  172. 8.29.3 Abbott Laboratories Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2021-2026)
  173. 8.29.4 Abbott Laboratories Antibacterial (Drug) Resistance Product Portfolio
  174. 8.29.5 Abbott Laboratories Recent Developments
  175. 8.30 AAIPharma Services
  176. 8.30.1 AAIPharma Services Company Information
  177. 8.30.2 AAIPharma Services Business Overview
  178. 8.30.3 AAIPharma Services Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2021-2026)
  179. 8.30.4 AAIPharma Services Antibacterial (Drug) Resistance Product Portfolio
  180. 8.30.5 AAIPharma Services Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Antibacterial (Drug) Resistance Value Chain Analysis
  2. 9.1.1 Antibacterial (Drug) Resistance Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Antibacterial (Drug) Resistance Production Mode & Process
  6. 9.2 Antibacterial (Drug) Resistance Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Antibacterial (Drug) Resistance Distributors
  9. 9.2.3 Antibacterial (Drug) Resistance Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst